High-performance Oncological Medicine Made in Germany

Setting a new standard in clinical cancer research - that is the goal of Bavarian researchers within the WERA alliance. As of today, the alliance is part of the National Centre for Tumour Diseases (NCT). On 24 November, they signed the federal-state administrative agreement on the NCT expansion: Federal Research Minister Bettina Stark-Watzinger, Baden-Württemberg's Science Minister Petra Olschowski and representatives of the ministries from Bavaria, Berlin, North Rhine-Westphalia and Saxony in Heidelberg. The National Centre for Tumour Diseases (NCT) has thus gained four new sites nationwide ÜBerlin, SouthWest (Tübingen/Stuttgart-Ulm), WERA (Würzburg with the partners Erlangen, Regensburg and Augsburg) and West (Essen/Cologne). Together with the existing sites in Heidelberg and Dresden, a total of six NCT sites are now cooperating with the German Cancer Research Centre (DKFZ) and University Medicine. The aim is to sustainably advance state-of-the-art clinical cancer research in Germany and thereby improve the treatment results and quality of life of cancer patients. WERA partners cover a care area of around eight million people.